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Abstract: Background: Most	available	studies	on	the	efficacy	of	topical	photodynamic	therapy	focus	on	short-	to	
medium-term results. Long-term data are scarce. 


















incidence	 is	 increasing	 worldwide.1 Treatment ap-
proaches for NMSC are predominantly curative and 
surgery	remains	the	mainstay	of	care.	However,	non-
surgical options have emerged as viable alternatives 
in	 patients	 who	 are	 either	 poor	 surgical	 candidates	
or have tumours that are not amenable to surgical 
treatment, namely multifocal lesions, extensive dis-
ease,	 lesions	 in	 cosmetically	 sensitive	 areas,	 or	 diffi-
cult	 locations.	 Topical	 photodynamic	 therapy	 (PDT)	
is	 a	 widely	 used,	 non-invasive	 treatment	 option	 for	
certain NMSCs. It is approved in Europe for the treat-
ment	of	actinic	keratosis,	Bowen’s	disease	(BD),	super-
ficial	basal	 cell	 carcinomas	 (sBCC),	and	 thin	nodular	
basal	cell	carcinomas	(nBCC).2	High	efficacy	is	report-
ed	 when	 using	 standardized	 protocols,	 along	 with	
superior	 cosmetic	 outcomes	 compared	 with	 other	
therapies.2 Nevertheless, long-term recurrence studies 
based on clinical practice are scarce.
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PATIENTS AND METHODS
Patients
A	 retrospective	 cohort	 study	 was	 conducted	






Treatment and evaluation protocol
MAL-PDT	was	delivered	using	a	standardized	
protocol	of	 two	treatments	one	week	apart,	 repeated	








entire lesion and extending 5mm beyond the clini-






ASA,	 Oslo,	 Norway),	 delivering	 a	 total	 dose	 of	 37-
40 J/cm2	(depending	on	the	guidelines	at	the	time	of	
treatment)	during	an	exposure	time	of	8’20”.
Clinical	 follow-up	was	 performed	 1,	 3,	 and	 6	
months	 following	 treatment	 and	 thereafter	 every	 6	
months.	The	primary	endpoint	was	clinically	observed	
recurrence in a previous PDT-treated area. Treated ar-
eas	were	identified	with	the	help	of	standard	illustra-
tions	on	which	the	lesions	had	been	signed	and	clinical	











Variables considered for survival analysis in-
cluded:	 patient’s	 age,	 gender,	 diagnosis,	 tumour	 lo-
cation	 and	 tumour	 size.	 Survival	 analysis	 was	 per-
formed	with	 the	Kaplan-Meier	method,	 followed	by	
nonparametric comparison of subgroups. Multivari-
ate	survival	analysis	was	conducted	by	applying	the	
Cox regression model to factors found to be predictive 
for	 recurrence	 on	 univariate	 analysis.	 Hazard-ratios	











was	 diagnosed	 in	 31	 tumours	 (40.3%),	 sBCC	 in	 44	
(57.1%),	 and	 nBCC	 in	 2	 (2.6%).	A	 diagnostic	 biopsy	
was	performed	in	53	(68.8%)	lesions.	There	was	a	his-







Three months after the last PDT treatment, com-
plete	response	was	observed	in	26	BD	lesions	(83.9%)	
and	in	33	sBCCs	(75%)	(Table	2).	Recurrence	was	ob-






























event approach, diagnosis and age subgroups exhib-
ited	 statistically	 significant	 differences	 in	 recurrence	
rates.	Moreover,	diagnosis	and	age	were	found	to	be	
independent predictors for clinical recurrence in mul-









27.9%	 at	 12	months,	 43%	 at	 24	months,	 48.2%	 at	 36	
months,	54%	at	48	months,	and	72.4%	at	60	months.	
Estimated	 recurrence	 rates	 for	 sBCC	 were	 5%	 at	 6	
months,	23.4%	at	12	months,	26.5%	at	24	months,	and	
30%	from	36	months	onward.	This	concludes	a	5-year	






An optimal cutpoint for the continuous covariate 
“age”	was	 calculated	using	martingale	 residuals,	 and	
set	at	57	years.	Patients	aged	57	or	younger	experienced	
higher	tumour	recurrence	in	comparison	with	older	pa-
tients through follow-up time	(p=0.039).	The	estimated	















Current guidelines propose PDT as an effective 
treatment for NMSC.2,3	 Efficacy,	 together	 with	 good	
848 Cabete J, Rafael M, Cravo M, Moura C, Sachse F, Pecegueiro M  
An Bras Dermatol. 2015;90(6):846-50.
Table 2: Treatment outcomes 3 months after treatment and long-term recurrence after complete response
Figure 1: A) Estimated	recurrence	rates	by	diagnosis;	
B) Estimated recurrence rates by age group
a
b
	 	 Bowen’s	disease	 Superficial	basal	cell	carcinoma	 p-value
Complete	Response,	n	(%)	 26/31	(83.9)	 	 33/44	(75)	 0.405
Partial	Response,	n	(%)	 4/31	(12.9)	 	 9/44	(20.5)	 0.539
No	Response,	n	(%)	 1/31	(3.2)	 	 2/44	(4.5)	 1
Recurrence,	n	(%)	 14/26	(53.8)	 	 11/33	(33.3)	 0.085
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tolerability, a tissue-sparing attitude, easy treatment 
protocols,	 good	 wound-healing	 and	 favourable	 cos-
mesis,	make	it	an	appealing	treatment	option	for	both	
doctors	and	patients.	While	widely	accepted	and	 in-
creasingly used, most available studies focus on short- 
to	medium-term	 results	 regarding	 both	 efficacy	 and	
cosmesis. Long-term data are still scarce.
Despite the many available options for BD 
management, there is no gold standard treatment 
for	 this	 intra-epidermal	 squamous	 cell	 carcinoma	
(SCC).2,3	However,	PDT	has	merited	a	strength	of	rec-
ommendation A and a level of evidence 1, in the light 
of presently available studies.2,3 Complete response 
rates	of	88-100%	were	reported	3	months	after	MAL-
PDT treatment for BD, thus justifying this rating.3 The 
majority of long-term studies report to	follow-up	peri-
ods	of	12-24	months	for	23-103	BD	lesions:	two	studies	
presented	 recurrence	 rates	 of	 13.6%	and	14.6%	at	 12	
months;	13%	of	 the	 lesions	 recurred	 in	a	16.6-month	
study;	 and	 a	 24-month	 follow-up	 analysis	 reported	
a	 29.3%	 recurrence	 rate.4-7 One report had a longer 
follow-up	period	of	50	months,	with	a	 recurrence	of	
11.6%	 in	 43	 of	 the	 lesions	 studied,	 all	 occurring	 in	
the	first	 year	 after	 treatment.8	 These	figures	 contrast	
with	 those	obtained	 in	 the	present	study.	Briefly,	 the	
estimated	 recurrence	 rates	 for	 BD	were	 27.9%	 at	 12	
months,	 43%	 at	 24	 months,	 54%	 at	 48	 months,	 and	
72.4%	at	60	months.	Whereas	these	data	are	a	product	
of a time-to-event approach through survival analy-
sis,	the	overall	recurrence	of	53.8%	(55.6%	in	biopsied	
lesions),	 is	also	consistently	high.	The	main	explana-
tion may reside in the particular characteristics of the 
population studied. As a tertiary care dermatology 
unit	within	an	oncology	hospital,	most	referrals	com-
prise	complex	cases,	patients	with	many	or	extensive	
lesions	 in	 difficult-to-treat	 areas,	 occasionally	 with	
ill-defined	 borders.	 Field	 carcinogenesis,	 a	 common	
background	 in	 the	 actinic	 damaged	 skin	 of	 patients	
with	 SCC,	may	 also	 account	 for	 the	high	 recurrence	
rates	in	these	patients,	especially	when	PDT	is	used	as	
a lesion-directed therapy.
Superficial	 therapies	 have	 been	 explored	 for	
the treatment of sBCC. Their increasing use in clinical 
practice is supported by the recognition of sBCC as a 
low-risk,	 slow-growing	 epidermal	 tumour.	 Similarly	






in	 a	 few	 studies.9	 Recurrence	 rates	 of	 9.3%	 and	 13%	
were	 reported	 in	 two	 12-month	 follow-up	 evalua-
tions.10,11	A	22%	recurrence	was	found	at	24	months	in	
one	study,	while	in	another,	a	time-to-event	approach	











of	 invasive	carcinoma	of	about	3–5%.16 This may ex-
plain	 the	 significantly	 higher	 recurrence	 rates	 of	 BD	
compared	with	sBCC	found	in	this	study.
Young	age	is	certainly	not	a	consensual	risk	fac-
tor in biomedical literature on NMSC.17-19 Most guide-
lines	do	not	consider	it	a	high-risk	factor	for	recurrence	
or aggressive behaviour. Nevertheless, age appears as 
a	predictor	 for	 recurrence	 in	 the	present	 study,	with	
an	 almost	 three-fold	 increased	 risk	 of	 recurrence	 in	
patients	aged	57	years	or	younger.	It	is	possible	that,	
once again, population characteristics have contribut-
ed	to	this	finding.	They	include	likely	actinic	damage	
sustained at an earlier age, suggested by the history of 
other	premalignant	and	malignant	skin	lesions.	There	
may	also	be	a	difference	in	response	to	PDT	between	
young	 and	 aged	 skin.	 Differences	 in	 skin	 thickness	
may	be	attributable	to	a	modified	penetration	of	both	
the	 photosensitizer	 and	 light.	Nevertheless,	 no	 pub-
lished data refer to such a discrepancy.
We	acknowledge	some	limitations	to	this	study.	
As a retrospective study, the amount of collectable 
data	is	limited.	For	instance,	it	would	have	been	fruit-
ful to detail personal history so as to include immu-
nosuppression or exposure to radiotherapy. Another 
limitation is the non-consistent execution of diagnos-
tic	biopsies	in	the	primary	and	recurrent	lesions.	How-
ever,	 this	study	was	undertaken	 in	a	setting	of	daily	
clinical practice. As a non-invasive treatment, derma-
tologists	may	instigate	PDT	without	first	resorting	to	
a biopsy. In routine clinical practice, the diagnosis is 
made	on	clinical	grounds,	usually	with	the	aid	of	der-
moscopy. Doubtful, ulcerated, or pigmented lesions, 
those occurring in immunosuppressed patients and 
recurrences, should be systematically biopsied.20 In 
this	study,	overall	recurrence	rates	were	similar	to	the	
recurrence rates of biopsy-proven lesions, both for the 
BD and sBCC groups. Nevertheless, given the higher 





and	 should	be	 taken	 into	 account	when	 choosing	 to	
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treat	 NMSC	with	MAL-PDT.	 The	 risk	 of	 recurrence	
was	significantly	higher	in	patients	with	BD	or	young-
er	 patients,	 highlighting	 the	 particularly	 low	 long-
term	efficacy	of	MAL-PDT	in	treating	BD	among	the	
population	studied.	Although	this	reflects	 the	reality	
of one institution, it stresses the need to establish an 
extended	 period	 of	 follow-up	 for	 patients	 with	 BD.	
While	surgery	should	be	considered,	we	believe	that	
PDT can be used for BD because recurrence usually 
occurs in smaller foci, easily managed by PDT or other 
treatment modalities. Field-directed therapy may also 
be	 a	 better	 option	 for	 patients	with	 actinic	 damage.	
Finally,	 efficacy,	 long-term	 recurrence,	 and	 cosmetic	
outcomes	should	be	weighted	to	patients’	characteris-
tics	(including	diagnosis	and	age),	and	the	therapeutic	
choice should be made on a case-by-case basis.q
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